Adefovir dipivoxil: Focus on its use in the treatment of chronic hepatitis B

Reviews in Gastroenterological Disorders

Volumn 5, Issue 2, 2005, Pages 89-100

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Adefovir dipivoxil; Aminotransferases; Hepatitis B; Lamivudine; Viral load

Indexed keywords

ADEFOVIR DIPHOSPHATE; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DRUG METABOLITE; HEPATITIS B(E) ANTIGEN; IBUPROFEN; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PARACETAMOL; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VANCOMYCIN; VIRUS DNA;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CARCINOGENICITY; CLINICAL TRIAL; COUGHING; CREATININE CLEARANCE; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; EMBRYOTOXICITY; ENZYME INHIBITION; FATTY LIVER; FEVER; FLATULENCE; FOOD DRUG INTERACTION; GLUCOSURIA; HEMATURIA; HEPATITIS B; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPERAMYLASEMIA; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TOXICITY; METABOLIC DISORDER; MUTAGENICITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT MONITORING; PHARYNGITIS; PRURITUS; REVIEW; SINUSITIS; TERATOGENICITY; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG MONITORING; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 21044450848     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Lok ASF, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39:857-861.
2. Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin N Am. 2004;33:629-654.
3. Younger HM, Bathgate AJ, Hayes PC. Nucleoside analogues for the treatment of chronic hepatitis B. Aliment Pharmacol Ther. 20004;20:1211-1230.
4. Keeffe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106.
5. Hepsera (adefovir) tablets [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2004.
6. Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis. 1997;176:406-413.
7. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology. 1997;40:295-303.
8. Delaney WE, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48:3702-3710.
9. Julander JG, Sidwell RW, Morrey JD. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 2002;55:27-40.
10. Cullen JM, Li DH, Brown C, et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother. 2001;45:2740-2745.
11. Tsiang M, Dale B, Rooney J, et al. Dynamics of hepatitis B virus clearance from the serum of patients treated with adefovir dipivoxil for 12 weeks [abstract]. Hepatology. 1998;28(4 pt 2): 492A.
12. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. 1999;29:1863-1869.
13. Yang H, Qi X, Das K, et al. In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase. Presented at: 39th Annual Meeting of the European Association for the Study of Liver; April 14-18, 2004; Berlin, Germany. Abstract 383.
14. Qi X, Snow A, Thibault V, et al. Week 144 resistance surveillance of adefovir dipivoxil-treated chronic hepatitis B patients. Presented at: 39th Annual Meeting of the European Association for the Study of Liver; April 14-18, 2004; Berlin, Germany. Oral presentation.
15. Westland CE, Yang H, Delaney WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003;38:96-103.
16. Westland CE, Yang H, Delaney WE, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepatitis. 2005;12:67-73.
17. Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 1997;176: 1517-1523.
18. Cundy KC, Barditchcrovo P, Walker RE, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995;39: 2401-2405.
19. Sokal E, Kelly D, Wirth S, et al. A phase 1-2 open-label study of the pharmacokinetics and safety of a single dose of adefovir dipivoxil in children and adolescents (aged 2-17) with chronic HBV infection. Presented at: 39th Annual Meeting of the European Association for the Study of Liver; April 14-18, 2004; Berlin, Germany. Abstract 445.
20. Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003;125:107-116.
21. Birnkrant D, Goldberger M. Briefing document for NDA 21-449: adefovir dipivoxil. Food and Drug Administration Web site. Available at: www.fda.gov. Accessed August 26, 2002.
22. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis-B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
24. Marcellin P, Goodman Z, Chang TT, et al. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil [abstract]. J Hepatol. 2002; 36(suppl):8.
25. Marcellin P, Chang TT, Lim SG, et al. Baseline ALT predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV) [abstract]. J Hepatol. 2002;36(suppl):122.
26. Marcellin P, Chang TT, Lim SG, et al. GS-98-437: a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results [abstract]. Hepatology. 2001;34(4 pt 2):340A.
27. Marcellin P, Chang TT, Lim SG, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; October 29-November 2, 2004; Boston, MA. Abstract 1135.
28. Hadziyannis S, Tassopolous N, Heathcote E, et al. GS-98-438: a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results [abstract]. J Hepatol. 2002;36(suppl):4.
29. Hadziyannis S, Tassopoulos N, Chang TT, et al. Three year results from a double-blind, randomized, placebo-controlled, study of adefovir dipivoxil (ADV) in HBeAg-negative chronic hepatitis B (CHB). Presented at: 39th Annual Meeting of the European Association for the Study of Liver. April 14-18, 2004; Berlin, Germany. Oral presentation.
30. Chang TT, Shiffman M, Tong M, et al. Durability of HBeAg seroconversion after adefovir dipivoxil (ADV) treatment for chronic hepatitis B (CHB). Presented at: 39th Annual Meeting of the European Association for the Study of Liver; April 14-18, 2004; Berlin, Germany. Abstract 424.
31. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126: 91-101.
32. Westland C, Gibbs C, Miller M, et al. Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy [abstract]. J Hepatol. 2002;36(suppl):7.
33. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81-90.
34. Perrillo R, Schiff E, Hann HWI, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine-preliminary 24 week results [abstract]. Hepatology. 2001;34(4 pt 2): 349A.
35. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients [abstract]. J Hepatol. 2002; 36(suppl):138.
36. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001;358:718-723.
37. Peters M, Schiff E, Benhamou Y, et al. Adefovir dipivoxil (ADV) demonstrates anti-viral efficacy and clinical benefit in the treatment of lamivudine resistant (LAM-R) chronic HBV: an analysis of four clinical trials [abstract]. Gastroenterology. 2002;123(1 suppl):71.
38. Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut. 2001;49:860-863.
39. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut. 2001;49: 436-440.
40. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation. 1999;68:1912-1914.
41. Ahmad J, Dodson SF, Balan V, et al. Adefovir dipivoxil suppresses lamivudine resistant hepatitis B virus in liver transplant recipients [abstract]. Hepatology. 2000;32(4 pt 2):292A.
42. Akay S, Karasu Z, Akyildiz M, Tokat Y. Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. Transplant Proc. 2004; 36:2768-2770.
43. Hosaka T, Suzuki F, Suzuki Y, et al. Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology. 2004;47: 362-369.
44. Toniutto P, Fumo E, Caldato M, et al. Favourable outcome of adefovir dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation. 2004;77:472-473.
45. Neff GW, O'Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transplant. 2004;10:1372-1378.
46. Marugan RB, Gomez LC, Serrano PL. Use of adefovir in the treatment of the chronic hepatitis V virus infection with resistance to lamivudine. Transplant Proc. 2003;35: 1841-1843.
47. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis; B in pre- and post-liver transplantation patients. Hepatology. 2003;38:1419-1427.
48. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66:1153-1158.
49. Hannon H, Bagnis CI, Benhamou Y, et al. The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant. 2004;19:386-390.